n the last few years, PCSK9 inhibitors have gained an increasing role in the treatment of dyslipidaemias,1 since monoclonal antibodies targeting PCSK9, namely evolocumab and alirocumab, were demonstrated to profoundly reduce plasma LDL-cholesterol levels and the incidence of major cardiovascular events in large randomized clinical trials of highrisk patients.2,
PCSK9 inhibition: not just LDL-cholesterol knock down: a glimmer for cancer / Patrono, C.; Volpe, M.. - In: EUROPEAN HEART JOURNAL. - ISSN 1522-9645. - 42:12(2021), pp. 1130-1131. [10.1093/eurheartj/ehab047]
PCSK9 inhibition: not just LDL-cholesterol knock down: a glimmer for cancer
Patrono C.;Volpe M.
2021
Abstract
n the last few years, PCSK9 inhibitors have gained an increasing role in the treatment of dyslipidaemias,1 since monoclonal antibodies targeting PCSK9, namely evolocumab and alirocumab, were demonstrated to profoundly reduce plasma LDL-cholesterol levels and the incidence of major cardiovascular events in large randomized clinical trials of highrisk patients.2,File allegati a questo prodotto
| File | Dimensione | Formato | |
|---|---|---|---|
|
Patrono_PCSK9-inhibition_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
179.29 kB
Formato
Adobe PDF
|
179.29 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
